A Billion-Dollar Aldosterone Synthase Inhibitor, an Oral KRASG12D Inhibitor Entering Development, and 14 More Molecules in the News
In this update of small molecules in the news we will cover recent:
(B/M)illion-Dollar Molecules: recent M&A’s, IPOs, and other fundraising
Molecules in Motion: clinical trial updates and FDA filings
Where Are They Now? updates on past Drug Hunter Molecules of the Month
Potential Upcoming Approvals: recent NDA filings and upcoming PDUFA dates
Want updates like this straight to your inbox? Sign up for our weekly newsletter here.
Million-Dollar Molecules
baxdrostat
This highly selective, oral aldosterone synthase (CYP11B2) inhibitor is being acquired by AstraZeneca via CinCor in a $1.8B transaction. The molecule is in several Ph. II trials (0.5-2 mg QD) for hypertension, CKD, and primary aldosteronism, appears to have demonstrated dose-dependent PK/PD and blood pressure response, and appears to be well-tolerated so far. CinCor licensed the molecule from Roche (RO6836191).